← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Alkermes, Inc.
Waltham, MA
$2,511,661
Total funding
3
Grants
Funding over time
peak $1.1M · FY2010–12$2M$1.5M$1M$500K$0
'10
'11
'12
Funding mix
By agency
NIH$2,511,661 · 3
By mechanism
R01$2,313,488 · 1
N43$99,193 · 1
R43$98,980 · 1
Investigators at Alkermes, Inc.
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
Not enough data
All-Time
Most funded here, all years
Largest grants
Clinical advancement of RDC-0313-buprenorphine: a novel approach to opioid recep$1,061,000
R01 · FY2010 · DA
Clinical advancement of RDC-0313-buprenorphine: a novel approach to opioid recep$1,037,900
R01 · FY2011 · DA
Clinical advancement of RDC-0313-buprenorphine: a novel approach to opioid recep$214,588
R01 · FY2012 · DA
SUSTAINED RELEASE NALTREXONE AS TRTMT FOR ALCM - SBIR I$99,193
N43 · FY2000 · AA
Novel, sustained-release naltrexone for opiate abuse$98,980
R43 · FY2001 · DA